Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.

Journal of experimental & clinical cancer research : CR - 10 Dec 2014

Xu Jian-Ming, Liu Xiao-Jing, Ge Fei-Jiao, Lin Li, Wang Yan, Sharma Manish R, Liu Ze-Yuan, Tommasi Stefania, Paradiso Angelo

Abstract excerpt

BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Kaplan-Meier Estimate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Predictive Value of Tests

Share to Proportional Hazards Models

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 25491325
DOI: 10.1186/s13046-014-0104-7
PMCID: PMC4272803

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.PMID 25491325Read ↗

Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue.Semantic proximity Read ↗

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.Semantic proximity Read ↗

KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Current and Emerging Biomarkers in Metastatic Colorectal CancerSemantic proximity Read ↗

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy SamplesSemantic proximity Read ↗

Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal CancerSemantic proximity Read ↗

Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancerSemantic proximity Read ↗

Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients.Semantic proximity Read ↗

Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicenter Cohort Study.Semantic proximity Read ↗

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.Semantic proximity Read ↗

Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.